MiRNA microarray data of drug-resistant breast cancer cell lines after chemotherapy
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA996976 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:The impact of three different chemodrugs (Adriamycin, Taxotere, Cytoxan) on the breast cancer cell lines (MDA-MB-231, MDA-MB-468, HCC1395) was analyzed compared to the parental cell by Affymetrix microarray
2024-01-25 | GSE237873 | GEO
Project description:To identify miRNAs involved in drug resistance of human breast cancer, a miRNA microarray was performed on 10 cases of drug resistant tissues and 10 cases of drug sensitive tissues. There were 29 differentially expressed miRNAs between drug resistant and drug sensitive tissues, including 22 significantly up-regulated and 7 down-regulated RNAs in drug resistant tissues compared to drug sensitive tissues. A signature of five miRNAs, including miR-23a-3p, miR-200c-3p, miR-214-3p, miR-638, and miR-451a was established. A risk score from the miRNA signature was calculated and patients were classified into high-risk and low-risk groups. Compared with the patients with low-risk scores, the patients with high risk scores showed resistant response to chemotherapy in the training, internal testing and independent sets.
2017-12-31 | GSE73736 | GEO
Project description:RNA expression profiles of drug-resistant TNBC cell lines after chemotherapy
| PRJNA958171 | ENA
Project description:Worldwide, breast cancer (BRCA) is the most common malignant tumor in women. Adriamycin (ADR) is considered one of the most effective agents for the treatment of BRCA, but its efficacy as a curative agent is compromised by intrinsic resistance and the acquisition of multidrug resistance characteristics during chemotherapy. The underlying mechanisms resulting in ADR resistance in BRCA remain poorly understood. Long non-coding RNA (lncRNA) are abnormally expressed in many cancers and are highly involved in its pathogenesis, including drug resistance. In order to systematically study the role of lncRNA in the resistance of BRCA cells to ADR, we used lncRNA expression microarray to establish gene expression profiles of ADR resistant cell lines and ADR sensitive cell lines.
2020-08-01 | GSE155478 | GEO
Project description:Efficacious cancer chemotherapeutic treatment requires both therapy delivery and retention by malignant cells. Cancer cell overexpression of the multidrug transmembrane transporter gene ABCB1 thwarts therapy retention, leading to a drug-resistant phenotype. We explored the phenotypic impact of ABCB1 overexpression in normal human mammary epithelial cells (HMECs) via acute adenoviral delivery and in breast cancer cell lines with stable integration of inducible ABCB1 expression. One hundred sixty-two genes were differentially expressed between ABCB1-expressing and GFP-expressing HMECs, including the gene encoding the cyclooxygenase-2 protein, PTGS2. Several breast cancer cell lines with inducible ABCB1 expression demonstrated sensitivity to the 5-lipoxygenase, cyclooxygenase-1/2 inhibitor tepoxalin in two-dimensional drug response assays, and combination treatment of tepoxalin either with chemotherapies or with histone deacetylase (HDAC) inhibitors improved therapeutic efficacy in these lines. Moreover, selection for the ABCB1-expressing cell population was reduced in three-dimensional co-cultures of ABCB1-expressing and GFP-expressing cells when chemotherapy was given in combination with tepoxalin. Further study is warranted to ascertain the clinical potential of tepoxalin, an FDA-approved therapeutic for use in domesticated mammals, to restore chemosensitivity and improve drug response in patients with ABCB1-overexpressing drug-resistant breast cancers.
2021-08-04 | GSE173411 | GEO
Project description:Breast cancer accounts for roughly 30% of all cancers in women worldwide, has a 15% death rate, and incidence rates are increasing at a rate of about 0.5% per year. Breast cancer comprises a heterogeneous group of tumor subtypes, whether defined by the histopathology of the primary tumor, the expression pattern of hormone receptors (estrogen and/or progesterone receptors; ER/PR) and epidermal growth factor receptor 2 (HER2), genetic alterations of transcriptomic traits. These patient-to-patient differences (as known as �쁦ntertumoral heterogeneity��, largely affect patient prognosis and treatment options. Alongside intertumoral heterogeneity, many studies reported that breast cancers heterogeneous consisting of many different cells or subclones of which different gene expression profiles within a patient�셲 primary tumor and individual metastases. These differences within the tumor are referred to as intratumor heterogeneity, which is caused by a combination of extrinsic factors from the tumor microenvironment and intrinsic parameters including genetic, epigenetic and transcriptomic traits, ability of proliferation, migration and invasion, cell plasticity, and the extent of stemness. These heterogeneities endow tumors with multiple capabilities and biological characteristics, making them more prone to metastasis, recurrence, and drug resistance. To overcome these facing challenges, understanding the proteome mechanisms behind transcriptome profiling from the aspect of treatment can help to improve resistance to cancer therapy. Recent proteomics technologies based on mass spectrometry enable an unbiased investigation of drug-induced changes in protein abundance and post-translational modifications. Several studies on resistance to chemotherapy have recently published data on mass spectrometry-based chemotherapeutic proteome profiling, which has the potential to discover molecular subtypes and related pathway features that may have been missed in prior transcriptome analyses. Nevertheless, few proteomics studies to date explore three types of drug-specific resistance of breast cancer signatures. In this study, we employed tandem mass tag (TMT) based proteomics technology to process the acquired mass spectrometry data to test the hypothesis that the chemotherapy in breast cancer cells may have distinct protein profiles that may result in their drug properties and new clinical implications. By unraveling the protein signatures across tamoxifen, doxorubicin, and paclitaxel and their relationship between drug-resistant cell lines and normal breast cancer cells, our study advances the understanding of drug-specific resistance and provides potential diagnostic and prognostic markers, as well as testable targets of therapy specific to breast cancer resistant cells.
2022-04-04 | PXD030881 | Pride
Project description:To identify miRNAs involved in drug resistance of human breast cancer, a miRNA microarray was performed on 5 cases of drug resistant tissues and 5 cases of drug sensitive tissues.The expression levels of totally 2019 miRNAs in 5 pairs of matched, drug resistant and drug sensitive tissues were examined by microarray. There were 27 differentially expressed miRNAs between drug resistant and drug sensitive tissues were identified of which there were 11 significantly up-regulated while the other 16 were down-regulated in drug resistant tissues compared to drug sensitive tissues. It was found that miR-489 was one of the most downregulated miRNAs in drug resistant tissues.
2017-08-01 | GSE71142 | GEO
Project description:To explore novel lncRNAs relative to chemo-resistance in breast cancer, we performed lncRNA microarray analysis using three anthracycline-resistant tissues and three anthracycline-sensitive tissues collected before neoadjuvant chemotherapy by Arraystar Human LncRNA Microarray V3.0.
2024-07-16 | GSE221060 | GEO
Project description:Chemotherapy resistance adversely impacts the treatment of some individuals with esophageal cancer. Identifying chemotherapy resistance might help tailor clinical treatments. In this study the impact of microRNAs on chemotherapy resistance in esophageal cancer was investigated. We used microarrays to detail the global programme of microRNA expression underlying chemotherapy resistance and identified distinct classes of up-regulated microRNAs in generated chemotherapy resistant cell lines. An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (SCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (FU) resistant variants vs. chemotherapy sensitive controls were compared using microarray. These results were further validated using qRT-PCR techniques (not shown in this submission).
2013-08-28 | E-GEOD-50224 | biostudies-arrayexpress
Project description:Tepoxalin increases chemotherapy efficacy in drug-resistant breast cancer cells overexpressing the multidrug transporter gene ABCB1
| PRJNA725471 | ENA